Compounded GLP-1 boom was a temporary loophole
The guest argued that Hims' explosive growth from compounded GLP-1 drugs in 2024 was built on exploiting an FDA shortage loophole that had a clear expiration date, which created significant risk when it closed.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.